CLINICAL_TRIALS
trial_result
· 2026-03-23
Clinical Trial Update: Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis [Phase 2, Phase 3]
Summary
Long-term safety results from a Phase 2/Phase 3 study of tofacitinib in children with Juvenile Idiopathic Arthritis have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Juvenile Idiopathic Arthritis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2026-03-23